Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Breast cancer
Closed
Phase 3
This study is looking to see if having a drug called everolimus alongside usual hormone therapy can reduce the risk of breast cancer coming back. It is for women whose cancer hasn't come back after at least 1 year of hormone therapy. And whose cancer:
Has receptors for the hormone oestrogen (is )
Doesn’t have receptors for the protein (HER2 negative).
This trial is supported by Cancer Research UK.
Recruitment start: 17 July 2015
Recruitment end: 5 March 2020
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor David Cameron
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Institute of Cancer Research (ICR)
Novartis
UNICANCER
This is Cancer Research UK trial number CRUK/13/010.
Last reviewed: 30 April 2020
CRUK internal database number: 10898
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
